Stock Track | Trevi Therapeutics Soars 7.15% in Pre-Market on Positive Analyst Coverage

Stock Track
03/18

Trevi Therapeutics Inc. (TRVI) experienced a significant pre-market surge of 7.15% on Wednesday, indicating strong investor optimism ahead of the regular trading session.

The upward movement appears to be driven by recent analyst actions. Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on the stock and set a price target of $18.00, reinforcing positive sentiment towards the company's prospects.

Concurrently, Morgan Stanley adjusted its outlook, cutting its price target on Trevi Therapeutics to $18.00 from $19.00. Despite the reduction, the maintained target price suggests continued analyst confidence in the stock's value, contributing to the pre-market rally.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10